The U.K.'s National Institute for Health and Clinical Excellence decided not to endorse GlaxoSmithKline and Genmab's leukemia drug Arzerra, citing lack of evidence on the drug's effectiveness compared with standard treatment. GSK recently failed to gain NICE recommendation for cancer medicine Tyverb and platelet drug Revolade.
GlaxoSmithKline has signed an agreement that will grant the drug giant access to biotech firm Anacor Pharmaceuticals' boron-based drug technology for the development of drugs against infectious diseases. As part of the deal, GSK will be selecting some drug candidates from Anacor's pipeline and marketing the drugs that prove successful in trials.
Australian biotech EvoGenix Ltd. said it has begun the second of three proposed projects with U.K.-based GlaxoSmithKline involving technologies used to develop antibodies for the market. The latest collaboration will attempt to "improve the properties of either an antibody or a protein to ... increase the effectiveness of drugs," EvoGenix CEO Dr. Merilyn Sleigh said.
GlaxoSmithKline and its partner, Adolor Corp., said the drug was designed to treat constipation problems tied to opioid painkillers. But negative findings from a Phase III study found 2.6% of patients treated with Entereg suffered heart problems compared with 1.1% of patients treated with placebos.